Formulation of Leuprolide at High Concentration for Delivery from a One-Year Duration Implant

Protein Formulation and Delivery, Second Edition

Volumn , Issue , 2007, Pages 153-176

  Stevenson, Cynthia L ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868194628     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849379529-10     Document Type: Chapter

References (95)

1. Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J PharmSci 2004; 93:1390-1402.
2. Stevens RC. Design of high-throughput methods of protein production for structural biology. Structure 2000; 8:R177-R185.
3. Shenoy B, Wang Y, Shan W, Margolin AL. Stability of crystalline proteins. Biotechnol Bioneng 2001; 73:358-369.
4. Cleland JL, Jones AJS. Stable formulations of recombinant human growth hormone and interferon-y for microencapsulation in biodegradable microspheres. Pharm Res 1996; 13:1464-1475.
5. Costantino HR, Firouzabadian L, Wu C, et al. Proteins spray freeze-drying. 2. Effect of formulation variables on particle size and stability. J PharmSci 2002; 91:388-395.
6. Costantino HR, Andya JD, Nguyen PA, et al. Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-ige monoclonal antibody. J PharmSci 1998; 87:1406-1411.
7. Wright JC, Stevenson CL, Stewart GR. Osmotic pumps-DUROS osmotic implants for humans. In: Mathiowitz E, ed. Encyclopedia of Controlled Drug Delivery. New York: John Wiley and Sons, 1999.
8. Stevenson CL, Theeuwes F, Wright JC. Osmotic implantable delivery systems. In: Wise D, ed. Handbook of Pharmaceutical Controlled Release Technology. New York: Marcel Dekker, Inc., 2000.
9. Fara JW, Ray N. Osmotic pumps. In: Praveen T, ed. Drug Delivery Devices. New York: Marcel Dekker, 1988:137-176.
10. Chien YW. Implantable therapeutic systems. Controlled Drug Delivery. New York: Marcel Dekker, 1987:481-522.
11. Zingerman JR, Cardinal JR, Chern RT, et al. The in vitro and in vivo performance of an osmotically controlled delivery system- IVOMEC SR bolus. J Control Release 1997; 47:1-11.
12. Siegel RA, Firestone BA. Mechanochemical approaches to self-regulating insulin pump design. J Control Release 1996; 11:181-192.
13. Baker R. Osmotic and mechanical devices. In: Baker R, ed. Controlled Release of Biologically Active Agents. New York: John Wiley and Sons, 1987:132-155.
14. Kaisary A, Tyrell CJ, Peeling WB. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67:502-508.
15. Huben RP, Murphy GP. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstibestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 1988; 62:1881-1887.
16. Soloway MS, Chodak G, Vogelzang NJ. Zoladex versus orchiectomy in treatment of advance prostate cancer: a randomized trial. Urology 1991; 37:46-51.
17. Adjie AL, Hsu L. Leuprolide and other LHRH analogues. In: Wang YF, Pearlman R, eds. Stability and Characterization of Protein and Peptide Drugs. New York: Plenum Press, 1993:159-199.
18. Nikiforovich GV, Marshall GR. Conformation-function relationships in LHRH analogs II. Conformations of LHRH peptide agonists and antoagonists. Int J Pept Protein Res 1993; 42:181-193.
19. Andersen NH, Hammem PK. A conformation-preference/potency correlation for GnRH analogs: NMR evidence. Bioorg Med Chem 1991; 5:263-266.
20. Houen PG. The solubility of proteins in organic solvents. Acta Chem Scand 1996; 50:68-70.
21. Zaks A, Klibanov AM. Enzymatic catalysis in nonaqueous solvents. J Bio Chem 1988; 263:3194-3201.
22. Zaks A, Klibanov AM. The effect of water on enzyme action in organic media. J Biol Chem 1988; 263:8017-8021.
23. Stevenson CL. Characterization of protein and peptide stability in non-aqueous solvents. Curr Pharm Biotechnol 2000; 1:165-182.
24. Chin JT, Wheeler SL, Klibanov AM. Protein solubility in organic solvents. Biotechnol Bioeng 1994; 44:140-145.
25. Frant MS. How to measure pH in mixed and nonaqueous solutions. Today’s Chemist at Work January 1995:39-42.
26. Martin A, Sarbrick J, Cammarata A. Physical Pharmacy. Physical Chemical Principles in the Pharmaceutical Sciences. Philadelphia, PA: Lea and Febiger, 1983.
27. Popovych O, Tomkins RPT. Nonaqueous Solution Chemistry. New York: John Wiley and Sons, 1981:221-224.
28. Schulze B, Klibanov AM. Inactivation and stabilization of subtilisins in neat organic solvents. Biotechnol Bioeng 1991; 38:1001-1006.
29. Bromberg LE, Klibanov AM. Transport of proteins dissolved in organic solvents across biomimetic membranes. Proc Natl Acad Sci USA 1995; 92:1262-1266.
30. Stevenson CL, Leonard JJ, Hall SC. Effect of peptide concentration and temperature on leuprolide stability in dimethyl sulfoxide. Int J Pharm 1999; 191:115-129.
31. Tan MM, Corley CA, Stevenson CL. Effect of gelation on the chemical stability and conformation of leuprolide. Pharm Res 1998; 15:1442-1447.
32. Hadden JM, Chapman D, Lee DC. A comparison of infrared spectra of proteins in solution and crystalline forms. Biochim Biophys Acta 1995; 1248:115-122.
33. Haris PI, Chapman D. The conformational analysis of peptide using fourier transform IR spectroscopy. Biopolymers 1995; 37:251-263.
34. Jackson M, Mantsch HH, Spencer JH. Conformation of magainin-2 and related peptide in aqueous solution and membrane environments probed by Fourier transform infrared spectroscopy. Biochemistry 1992; 31:1289-1293.
35. Brauner JW, Mendelsohn R, Prendergast FG. Attenuated total reflectance fourier transform infrared studies on the interaction of melittin, two fragments of melittin and 8-hemolsin with phosphatidylcholines. Biochemistry 1987; 26:8151-8158.
36. Seeback D, Thaler A, Beck AK. Solubilization of peptides on non-polar organic solvents by the additions of inorganic salts: facts and implications. Helvetica Chemica Acta 1989; 72:857-867.
37. Rariy RV, Klibanov AM. Protein refolding in predominantly organic media markedly enhanced by common salts. Biotechnol Bioeng 1999; 62:704-710.
38. Fransson J, Hallen D, Florin-Robertsson E. Solvent effects on the solubility and physical stability of human insulin like growth factor I. Pharm Res 1997; 14:606-612.
39. Kim J, Dordick JS. Unusual salt and solvent dependence of a protease from an extreme halophile. Biotechnol Bioeng 1997; 55:471-479.
40. Collins KD, Washabaugh MW. The hofmeister effect and the behavior of water at interfaces. Q Rev Biophys 1985; 14:323-422.
41. Powell MF, Fleitman J, Sanders LM, Si VC. Peptide liquid crystals: inverse correlation of kinetic formation and thermodynamic stability in aqueous solution. Pharm Res 1994; 11:1352-1354.
42. Powell MF, Sanders LM, Rogerson A, Si V. Parenteral peptide formulations: chemical and physical properties of native luteinizing hormone-releasing hormone (LHRH) and hydrophobic analogues in aqueous solution. Pharm Res 1991; 8:1258-1263.
43. Stevenson CL, Bennett DB, Lechuga-Ballesteros D. Liquid crystals in pharmaceutical systems: the relevance of partially ordered systems. J PharmSci 2005; 94:1861-1880.
44. Samulski ET, DuPre DB. Lyotropic polymeric liquid crystals. J Chim Physique 1983; 80:25-30.
45. Brown GH, Crooker PP. Liquid crystals a colorful state of matter. C&EN January 1983; 24-38.
46. Chandrasekhar S. Liquid Crystals. Cambridge: Cambridge University Press, 1992.
47. Rose S, Nelson JF. A continuous long-term injector. Aust J Exp Biol 1955; 33:415-420.
48. Hall SC, Tan MM, Leonard JJ, Stevenson CL. Characterization and comparison of leuprolide degradation profiles with water and dimethyl sulfoxide. J Pept Res 1999; 53:432-441.
49. Motto MG, Hamburg PF, Graden DA, Shaw CJ, Cotter ML. Characterization of the degradation products of LHRH. J PharmSci 1991; 80:419-423.
50. Oyler AR, Naldi RE, Lloyd JR, Graden DA, Shaw CJ, Cotter ML. Characterization of the solution degradation products of histerelin, a gonatotropin releasing hormone (LH/RH) agonist. J PharmSci 1991; 80:271-275.
51. Okada J, Seo T, Kasahara F, Takeda K, Kondo S. New degradation product of Des-Gly10-NH2-LH-RH-Ethylamide (fertirelin) in aqueous solution. J PharmSci 1991; 80:167-170.
52. Adam W, Ahrweiler M, Saiter M, Schmiedeskamp B. Oxidation of indoles by singlet oxygen and dimethyl dioxirane: isolation of indole dioxetanes and epoxides by stabilization through nitrogen acylation. Tetrahedron Lett 1993; 34:5247-5250.
53. Adam W, Ahrweiler M, Peters K, Schmiedeskamp B. Oxidation of N-acylindoles by dimethyldioxirane and singlet oxygen: substituent effects on thermally pesistent indole epoxides and dioxtetanes. J Org Chem 1994; 59:2733-2739.
54. Zhang X, Foot CS. 1,2-dioxetane formation in photooxygenation of N-acylation indole derivatives. J Org Chem 1993; 58:47-51.
55. Zhang X, Zhang N, Schuchmann HP, von Sonntag C. Pulse radiolysis of 2-mercapto-ethanol in oxygenated aqueous solution. Generation and reactions of the thiylperoxyl radical. J Phys Chem 1994; 98:6541-6547.
56. Itakkura K, Uchida K, Kawakishi S. Selective formation of oxindole and formylkyn-urenine type products from tryptophan and its peptides treated with a superoxide generating system in the presence of iron (III)-EDTA: a possible involvement with iron-oxygen complex. Chem Res Toxicol 1994; 7:185-190.
57. Li SH, Schoenich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng 1995; 48:490-500.
58. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res 1989; 6:903-913.
59. Nashef AS, Osuga DT, Lee HS, Ahmed AI, Whitaker JR, Feeney RE. Effects of alkali on proteins. Disulfides and their products. J Agric Food Chem 1977; 25:245-251.
60. Schrier JA, Kenley RA, Williams R, et al. Huberty. Degradation pathways for recombinant human macrophage colony stimulating factor in aqueous solution. Pharm Res 1993; 10:933-944.
61. Stevenson CL, Leonard JJ, Mabanglo D, et al. Effect of moisture, oxygen and irradiation on leuprolide stability. AAPS PharmSci 1998; 1:S541.
62. Lide DR. Handbook of Chemistry and Physics. 75th ed. Ann Arbor: CRC Press, 1995.
63. Brennan TV, Clarke S. Spontaneous degradation of polypeptides at aspartyl and aspa-raginyl residues: effects of the solvent dielectric. Protein Sci 1993; 2:331-338.
64. Capasso S, Mazzarella L, Zagari A. Deamidation via cyclic imide of asparaginyl peptide: dependence of salts, buffers and organic solvents. Pept Res 1991; 4:234-238.
65. Fransson J, Florin-Robertsson E, Axelsson K, Nyhlen C. Oxidation of human insulin like growth factor I in formulation studies: kinetics of Methionine oxidation in aqueous solution and in solid state. Pharm Res 1996; 13:1252-1257.
66. Theeuwes F. Elementary osmotic pump. J PharmSci 1975; 64:1987-1991.
67. Theeuwes F, Yum SE. Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations. Ann Biomed Eng 1976; 4:343-353.
68. Wright JC, Leonard ST, Stevenson CL, et al. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J Control Release 2001; 75:1-10.
69. Crawford E, DeAntonio EP, Labrie F, Schroder FH, Geller J. Endocrine therapy of prostate: optimal form and appropriate timing. J Clin Endocrinol Metab 1995; 80:1062-1078.
70. Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999; 26:162-173.
71. Sharifi R, Knoll LD, Smith J, Kramolowsky E. Leuprolide acetate (30 mg depot every 4 months) in the treatment of advance prostate cancer. Urology 1998; 51:271-276.
72. Sarosdy MF, Schelhammer PP, Soloway MS, et al. Endocrine effects, efficacy and tolerability of a 10.8 mg depot formulation of goserelin acetate administered every 13 weeks to patients with advance prostate cancer. BJU Int 1999; 83:801-806.
73. Fowler JE, Gottesman JE, Bardot SF, et al. Duros leuprolide implantable therapeutic systems in patients with advanced prostate cancer: 114-month results of a phase I/II dose-ranging study. J Urol 1999; 161:S300.
74. Fowler JE, Gottesman JE, Reid CF, Andriole GL, Soloway MS. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol 2000; 164:730-734.
75. Cukierski MJ, Johnson PA, Beck JC. Chronic (60 week) toxicity study of DUROS leuprolide implants in dogs. Int J Toxicol 2001; 20:369-381.
76. Wright J, Chen G, Cukierski M, et al. Duros leuporlide implant for continuous one-year treatment of prostate cancer. Proc Int Symp Control Release Bioact Mater 1998; 25:516-517.
77. Lee KC, Lee YJ, Song HM, Chun CJ, DeLuca PP. Degradation of synthetic salmon calcitonin in aqueous solution. Pharm Res 1992; 9:1521-1523.
78. Physicians Desk Reference. Medical Economics. New Jersey: Montvale, 1998.
79. Cudd A, Arvinte T, Gaines Das RE, Chinni C, MacIntyre I. Enhance potency of human calcitonin when fibrillation is avoided. J PharmSci 1995; 84:717-719.
80. Arvinte T, Cudd A, Drake AF. The structure and mechanism of formation of human calcitonin fibrils. J Biol Chem 1993; 268:6415-6422.
81. Stevenson CL, Tan MM. Solution stability of salmon calcitonin at high concentration for delivery in an implantable system. J Pept Res 2000; 55:129-139.
82. Stevenson C, Fereira P, Tan M, Ayer R, Dehnad H, Berry S. Glucagon-like peptide suspension stability and delivery from a DUROS implant. Proceedings of the 27th International Symposium on Controlled Release of Bioactive Materials, 2000, Vol. 27:986-987.
83. Berry SA, Fereira P, Tan M, et al. To investigate zero order delivery profiles of protein/peptide suspension formulations from osmotically driven implantable pumps. AAPS PharmSci 2000; 2:S2248.
84. Johnson HM, Bazer FW, Szente BE, Jarpe MA. How interferons fight disease. Sci Am May 1998; 68-75.
85. Knepp VM, Muchnik A, Oldmark S, Kalashnikova L. Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures. Pharm Res 1998; 15:1090-1095.
86. Ip AY, Arakawa T, Silvers H, Ransone CM, Niven RW. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization. J PharmSci 1995; 84:1210-1214.
87. www.intarcia.com
88. Lawn RM. The molecular genetics of hemophilia: blood clotting factors VIII and IX. Cell 1985; 42:405-406.
89. Smith KL. Factor IX concentrates: the new products and their properties. Transfus Med Rev 1992; 6:124-136.
90. Volkin DB, Staubli A, Langer R, Klibanov AM. Enzyme thermoinactivation in anhydrous organic solvents. Biotechnol Bioeng 1991; 37:843-853.
91. Desai UR, Klibanov AM. Assessing the structural integrity of a lyophilized protein in organic solvents. J Am Chem Soc 1995; 117:3940-3945.
92. Griebenow K, Klibanov AM. On protein denaturation in aqueous-organic mixtures but not pure organic solvents. J Am Chem Soc 1996; 118:11698–11700.
93. Santos AM, Vidal M, Pacheco Y, et al. Effect of crown ethers on structure, stability, activity and enantioselectivity of subtilisin carlsberg in organic solvents. Biotechnol Bioeng 2001; 4:295–308.
94. Mishra P, Griebenow K, Klibanov AM. Structural basis for the molecular memory of imprinted proteins in anhydrous media. Biotechnol Bioeng 1996; 52:609–614.
95. Halling PJ. High-affi nity binding of water by proteins is similar in air and in organic solvents. Biochim Biophys Acta 1990; 1040:225–228.